"preclinical antibody Development for prevention of AMR bacteria
Lead Research Organisation:
Imperial College London
Department Name: Infectious Disease
Abstract
I hypothesise that mAbs can protect against Gram negative bacterial infections in the lung. In order to test this hypothesis I will first develop mouse models of bacterial lung infection. Once those models have been established I will use them to test the efficacy of the first generation human mAb from Kymab, the industrial partner for my CASE studentship. This antibody targets poly-N-acetylglucosamine, a capsular bacterial polysaccharide that is highly conserved (Skurnik et al., 2016). In theory, this mAb should be broadly acting across a range of Gram negative bacteria. After testing the first generation mAbs in vivo I will go to Kymab to generate second generation mAbs. I will then test the efficacy of these second generation mAbs in comparison to the first generation mAbs.
Organisations
People |
ORCID iD |
John Tregoning (Primary Supervisor) |
Studentship Projects
Project Reference | Relationship | Related To | Start | End | Student Name |
---|---|---|---|---|---|
BB/M011178/1 | 30/09/2015 | 25/02/2025 | |||
2368490 | Studentship | BB/M011178/1 | 28/09/2018 | 23/12/2022 |